MYC and neoplasm: Another approach is the “vaccination” of wild-type mice with α-galactosylceramide-loaded (a synthetic CD1d-dependent NK T-cell ligand) and irradiated Eμ-Myc lymphoma cells to lower tumor burden and increase survival after transplantation of malignant cells from Eμ-Myc transgenic mice [48].